B62The road to success is paved with dolutegravir: Dolutegravir treatment success among in children and adolescents living with HIV (CALHIV) at the Baylor Tanzania Centres of ExcellenceOn-demand oral abstract sessionARV management strategies in paediatric and adolescent populations
B67Neuropsychiatric manifestations and sleep disturbances in children and adolescents randomised to dolutegravir-based ART vs standard-of-care in the ODYSSEY trialOn-demand oral abstract sessionMental health and neurocognition in paediatric and adolescent populations
C27Global adoption of guidelines on and use of oral pre-exposure prophylaxis (PrEP): current situation and future projectionsOn-demand oral abstract sessionPrEP
C27Early predictors of seroconversion among enrolees in a PrEP program in Brazil, Mexico and Peru ' the IMPREP Demonstration studyOn-demand oral abstract sessionPrEP
C27Comparing adherence to HIV Pre-Exposure Prophylaxis (PrEP) among new, male PrEP users initiating F/TAF vs. F/TDFOn-demand oral abstract sessionPrEP
C27Variation in preferences for long-acting injectable PrEP among US men who have sex with men: a latent class analysisOn-demand oral abstract sessionPrEP
C27Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEPOn-demand oral abstract sessionPrEP
C27SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine- based PrEP in 2020 ' a sub-study of PREVENIR-ANRS and SAPRIS-SeroOn-demand oral abstract sessionPrEP
C35Demand creation and HIV self-testing delivery during COVID-19 contingency measures of physical distancing among adolescents' key population enrolled in PrEP in BrazilOn-demand oral abstract sessionHIV prevention adaptations during COVID-19
C27Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019 ' June 2020On-demand oral abstract sessionPrEP
41 - 50 of 870 items